ACADIA PHARMACEUTICALS INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ACADIA PHARMACEUTICALS INC. (ACAD) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $9.45 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-26
- ACADIA PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $2.50M.
- ACADIA PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $6.18M, a 47.71% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $4.70M, a 155.63% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was -$6.66M.
- ACADIA PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $9.45M, a 326.06% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $2.22M, a 8.14% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.05M, a 47.02% decline from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $3.87M, a 77.59% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $9.45M 10-K · filed 2026-02-26 | ||||
| 2025-06-30 | $2.50M 10-Q · filed 2025-08-07 | $8.68M 10-Q · filed 2025-08-07 | $13.38M derived: sum of 3 quarters · filed 2026-02-26 | $6.71M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-03-31 | $6.18M 10-Q · filed 2025-05-08 | $10.88M derived: sum of 2 quarters · filed 2026-02-26 | $4.21M derived: sum of 3 quarters · filed 2026-02-26 | $4.21M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | $4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.97M derived: sum of 2 quarters · filed 2026-02-26 | -$1.97M derived: sum of 3 quarters · filed 2026-02-26 | $2.22M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$6.66M 10-Q · filed 2024-11-07 | -$6.66M derived: sum of 2 quarters · filed 2025-08-07 | -$2.48M 10-Q · filed 2024-11-07 | -$641.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $4.18M 10-Q · filed 2025-08-07 | $6.02M derived: sum of 3 quarters · filed 2025-08-07 | $6.02M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $4.18M 10-Q · filed 2025-05-08 | $6.02M derived: sum of 2 quarters · filed 2025-05-08 | $6.02M derived: sum of 3 quarters · filed 2025-05-08 | $5.93M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.84M derived: sum of 2 quarters · filed 2025-02-27 | $1.75M derived: sum of 3 quarters · filed 2025-02-27 | $2.05M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | -$90.00K derived: sum of 2 quarters · filed 2024-11-07 | $214.00K 10-Q · filed 2024-11-07 | $884.00K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$90.00K 10-Q · filed 2024-08-07 | $90.00K 10-Q · filed 2023-08-03 | $214.00K 10-Q · filed 2024-08-07 | $884.00K derived: sum of 3 quarters · filed 2024-08-07 | $1.76M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $304.00K 10-Q · filed 2024-05-09 | $974.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.85M derived: sum of 3 quarters · filed 2024-05-09 | $2.73M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $670.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.55M derived: sum of 2 quarters · filed 2024-02-28 | $2.43M derived: sum of 3 quarters · filed 2024-02-28 | $3.87M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $880.00K 10-Q · filed 2023-11-03 | $1.76M derived: sum of 2 quarters · filed 2023-11-03 | $3.20M 10-Q · filed 2023-11-03 | $2.93M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $881.00K 10-Q · filed 2023-08-03 | $2.32M 10-Q · filed 2023-08-03 | $2.05M derived: sum of 3 quarters · filed 2023-08-03 | $2.22M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $1.44M 10-Q · filed 2023-05-08 | $1.17M derived: sum of 2 quarters · filed 2023-05-08 | $1.33M derived: sum of 3 quarters · filed 2023-05-08 | $18.71M derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | -$271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$105.00K derived: sum of 2 quarters · filed 2023-02-28 | $17.27M derived: sum of 3 quarters · filed 2023-02-28 | $17.27M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $166.00K 10-Q · filed 2022-11-03 | $17.54M derived: sum of 2 quarters · filed 2022-11-03 | $17.54M 10-Q · filed 2022-11-03 | $35.43M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $17.38M 10-Q · filed 2022-08-09 | $17.38M 10-Q · filed 2022-08-09 | $35.26M derived: sum of 3 quarters · filed 2022-08-09 | $76.45M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $17.42M 10-Q · filed 2022-05-05 | $17.89M derived: sum of 2 quarters · filed 2022-05-05 | $59.08M derived: sum of 3 quarters · filed 2022-05-05 | $59.18M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $468.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $41.66M derived: sum of 2 quarters · filed 2022-03-01 | $41.76M derived: sum of 3 quarters · filed 2022-03-01 | $42.04M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $41.19M 10-Q · filed 2021-11-09 | $41.30M derived: sum of 2 quarters · filed 2021-11-09 | $41.57M 10-Q · filed 2021-11-09 | $42.16M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $105.00K 10-Q · filed 2021-08-05 | $381.00K 10-Q · filed 2021-08-05 | $965.00K derived: sum of 3 quarters · filed 2021-08-05 | $1.83M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $276.00K 10-Q · filed 2021-05-06 | $860.00K derived: sum of 2 quarters · filed 2021-05-06 | $1.72M derived: sum of 3 quarters · filed 2021-05-06 | $1.92M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.45M derived: sum of 2 quarters · filed 2021-02-25 | $1.65M derived: sum of 3 quarters · filed 2021-02-25 | $13.40M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $864.00K 10-Q · filed 2020-11-04 | $1.06M derived: sum of 2 quarters · filed 2020-11-04 | $12.81M 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $200.00K 10-Q · filed 2020-08-06 | $11.95M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $11.75M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |